Alpha¹ by KaimenConfidential

Kaimen Rigor review

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.

Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J, SURMOUNT-OSA Investigators

DOI: 10.1056/NEJMoa2404881
Record issued: 2026-08-16
Engine: 7.39.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/af44215f-febb-4714-b35b-93191fd4fb75 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on the change in apnea-hypopnea index (AHI), a surrogate endpoint for obstructive sleep apnea. Although the paper cites clinical significance thresholds for AHI, it does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking AHI reduction to hard clinical outcomes such as cardiovascular events or mortality. The paper acknowledges that PAP therapy, which improves AHI, has not been shown to reduce cardiovascular outcomes, and the trials were not designed to assess long-term cardiovascular outcomes.
“The primary end point was the change in the apnea–hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper reports two well-designed phase 3 randomized controlled trials with rigorous methodology, clear reporting of demographics, ethical approvals, and statistical analyses. The main weakness is the vague data availability statement, which lacks specific mechanisms for data access. Minor reporting gaps include the absence of statistical software identification and explicit CONSORT adherence.

Both reviewers classified the study as interventional, and this synthesis adopts that classification. The evaluation covered all eight dimensions; several sub-criteria were marked not applicable for human trials (e.g., replicate distinction, controls, species/strain, housing, IACUC). The statistics verification recomputed only 2 tests (both consistent); other statistics were not machine-verified. Citation check found no retracted or unresolved references.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Primary endpoint trial 1: treatment difference in AHI change
“for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001)”
Find in source
Taken as given: The estimate is the treatment difference in means.; The 95% CI is two-sided.; The test is two-sided.
Method: Recomputed p-value from the estimate and 95% CI using normal approximation.
How we recomputed it: pCI(-20.0, -25.8, -14.2, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Primary endpoint trial 2: treatment difference in AHI change
“for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9), (P<0.001)”
Find in source
Taken as given: The estimate is the treatment difference in means.; The 95% CI is two-sided.; The test is two-sided.
Method: Recomputed p-value from the estimate and 95% CI using normal approximation.
How we recomputed it: pCI(-23.8, -29.6, -17.9, 0)

lowinternal contradiction
In Table 1, the total N for trial 1 is 234, but the sum of tirzepatide (114) and placebo (120) is 234, which is consistent. However, in Table 4, the N for tirzepatide in trial 2 is 119, while in Table 1 it is 120. This discrepancy is likely due to one participant not receiving the drug, but it is not explicitly explained.
“Tirzepatide N = 119 Placebo N = 114”
Table 4Find in source

Overstated conclusions

1 finding · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

7 major claims checked against the paper's own evidence: all adequately supported.

supportedReviewer 1
Tirzepatide reduced AHI in adults with moderate-to-severe OSA and obesity.
The primary endpoint results show significant reductions in AHI in both trials.
Evidence: Trial 1: treatment difference −20.0 events/hr (95% CI −25.8 to −14.2, P<0.001); Trial 2: −23.8 events/hr (95% CI −29.6 to −17.9, P<0.001).
In trial 1, the mean change in AHI at week 52 was −25.3 events per hour ... for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).
Abstractreviewer’s wording
supportedReviewer 1
Tirzepatide reduced body weight, hypoxic burden, hsCRP, and systolic blood pressure.
Key secondary endpoints show significant improvements in these measures.
Evidence: Table 2 reports significant changes in body weight, hypoxic burden, hsCRP, and systolic blood pressure.
“tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure”
ConclusionFind in source
supportedReviewers 1, 2
Tirzepatide improved sleep-related patient-reported outcomes.
Pooled PROMIS-SRI and PROMIS-SD scores improved significantly.
Evidence: Table 3 shows significant improvements in PROMIS-SRI and PROMIS-SD.
“improved sleep-related patient-reported outcomes”
ConclusionFind in source
supportedReviewers 1, 2
The safety profile of tirzepatide was consistent with previous trials.
Adverse events were mostly gastrointestinal and mild-to-moderate, consistent with known profile.
Evidence: Safety results in Table 4 and discussion.
“The safety profile of tirzepatide was consistent with that observed in previous trials.”
Discussion ¶3Find in source
supportedReviewer 2
Tirzepatide reduced the AHI in adults with moderate-to-severe obstructive sleep apnea and obesity.
The primary endpoint showed a significant reduction in AHI in both trials, with treatment differences of -20.0 and -23.8 events/hour, both with p<0.001.
Evidence: Primary endpoint results in Table 2 and Figure 1.
In trial 1, the mean change in AHI at week 52 was −25.3 events per hour ... with tirzepatide and −5.3 events per hour ... with placebo, for an estimated treatment difference of −20.0 events per hour ... (P<0.001).
Abstractreviewer’s wording
supportedReviewer 2
Tirzepatide reduced body weight.
Key secondary endpoint showed significant percent change in body weight in both trials.
Evidence: Table 2: Percent change in body weight -17.7% vs -1.6% in trial 1, -19.6% vs -2.3% in trial 2.
“Percent change in body weight (95% CI) −17.7 (−19.0 to −16.3) −1.6 (−2.9 to −0.2) −16.1 (−18.0 to −14.2)”
Table 2Find in source
supportedReviewer 2
Tirzepatide reduced hypoxic burden, hsCRP, and systolic blood pressure.
Key secondary endpoints showed significant improvements in these measures in both trials.
Evidence: Table 2: Changes in hypoxic burden, hsCRP, and systolic blood pressure all showed significant treatment differences.
“Change in sleep apnea–specific hypoxic burden at wk 52 (95% CI) — % min/hr −95.2 (−103.2 to −87.2) −25.1 (−44.3 to −5.9) −70.1 (−90.9 to −49.3)”
Table 2Find in source

Premise concern: surrogate not validated for clinical benefit.

INADEQUATESurrogate endpoint
The primary efficacy claim is based on the change in apnea-hypopnea index (AHI), a surrogate endpoint for obstructive sleep apnea. Although the paper cites clinical significance thresholds for AHI, it does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking AHI reduction to hard clinical outcomes such as cardiovascular events or mortality. The paper acknowledges that PAP therapy, which improves AHI, has not been shown to reduce cardiovascular outcomes, and the trials were not designed to assess long-term cardiovascular outcomes.
“The primary end point was the change in the apnea–hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline.”
Find in source
ADEQUATEEffect size
The treatment effect on AHI is large and statistically significant: in trial 1, the mean change was -25.3 events/hour with tirzepatide vs -5.3 with placebo (difference -20.0, 95% CI -25.8 to -14.2); in trial 2, -29.3 vs -5.5 (difference -23.8, 95% CI -29.6 to -17.9). The paper anchors this as clinically meaningful by citing the American Academy of Sleep Medicine threshold of AHI ≥15 events/hour and a 50% improvement as clinically relevant. Additionally, a substantial proportion of participants achieved AHI <5 or 5-14 with ESS ≤10 (up to 50.2%).
“This change is considered clinically relevant; the American Academy of Sleep Medicine defines the clinical significance threshold for the AHI as 15 or more events per hour, and other sources have proposed a 50% improvement in AHI as clinically relevant.”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on the pathophysiology of OSA, limitations of existing treatments (PAP, mandibular advancement, surgery), and the role of obesity. It references prior tirzepatide trials showing weight loss and cardiovascular benefits. The rationale for using tirzepatide in OSA is logically developed. Limitations of prior research are implicitly addressed by noting the lack of approved pharmacotherapy and the need for holistic treatment.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale linking obesity to obstructive sleep apnea and the potential of tirzepatide.

Evidence

“Randomized, controlled trials have failed to show that PAP reduces occurrences of adverse cardiovascular outcomes and death.”

Introduction ¶1Find in source

“Treatment with tirzepatide has led to significant reductions in excess body weight, improvements in blood pressure, and reductions in markers of inflammation and vascular endothelial dysfunction, and may have the potential to be efficacious in persons with obstructive sleep apnea.”

Introduction ¶3Find in source

“Excess adiposity is a major reversible etiologic risk factor for obstructive sleep apnea and its complications.”

Introduction ¶2Find in source

PASSReviewer 2· 95% conf

The paper establishes a clear scientific premise: OSA is a common disorder with limited pharmacologic options, and obesity is a reversible risk factor, providing a strong rationale for testing tirzepatide.

Evidence

“Randomized, controlled trials have failed to show that PAP reduces occurrences of adverse cardiovascular outcomes and death.”

Introduction ¶1Find in source

Introduction ¶2Find in source

“Here we report the results of the SURMOUNT-OSA phase 3 trials evaluating the safety and efficacy of tirzepatide for the treatment of adults with obstructive sleep apnea and obesity.”

Introduction ¶2Find in source

Randomization was conducted via a web-based interactive response system with stratification by trial, region, baseline AHI severity, and sex. Participants, investigators, and sponsor were blinded. A sample size calculation provided at least 90% power. Inclusion/exclusion criteria were pre-specified. The analysis population (ITT) and missing data handling were defined. As a human RCT, replicate_distinction, controls, and independent_replication are not applicable.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trials are rigorously designed with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Randomization was conducted by means of a Web-based interactive response system and stratified according to trial, country or geographic region, baseline AHI severity category, and sex.”

MethodsFind in source

“Participants, investigators, and the sponsor were unaware of trial-group assignment.”

MethodsFind in source

“We calculated that a sample size of 206 participants per trial would provide the trial with at least 90% power to show the superiority of tirzepatide to placebo relative to the primary end point at a two-sided significance level of 0.05.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trials are rigorously designed with proper randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Randomization was conducted by means of a Web-based interactive response system and stratified according to trial, country or geographic region, baseline AHI severity category, and sex.”

MethodsFind in source

“Participants, investigators, and the sponsor were unaware of trial-group assignment.”

MethodsFind in source

Statistical analysisFind in source

Sex is reported for each group, and both sexes are enrolled, so sex_justified is not applicable. Age, BMI, and health status (e.g., hypertension, prediabetes) are reported. Demographics include race/ethnicity. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Demographic and baseline characteristics, including sex, age, BMI, and race, are reported in detail.

Evidence

“Female sex — no. (%) 36 (31.6) 41 (34.2) 77 (32.9) 33 (27.5) 32 (27.8) 65 (27.7)”

Table 1Find in source

“Age — yr 47.3±11.0 48.4±11.9 47.9±11.5 50.8±10.7 52.7±11.3 51.7±11.0”

Table 1Find in source

“White 74 (64.9) 80 (66.7) 154 (65.8) 85 (70.8) 86 (75.4) 171 (73.1)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and baseline characteristics, including sex, age, BMI, and comorbidities, are thoroughly reported.

Evidence

“Female sex — no. (%) 36 (31.6) 41 (34.2) 77 (32.9) 33 (27.5) 32 (27.8) 65 (27.7)”

Table 1Find in source

“Age — yr 47.3±11.0 48.4±11.9 47.9±11.5 50.8±10.7 52.7±11.3 51.7±11.0”

Table 1Find in source

“Race or ethnic group — no. (%) American Indian or Alaska Native 9 (7.9) 9 (7.5) 18 (7.7) 10 (8.3) 9 (7.9) 19 (8.1)”

Table 1Find in source

The protocol was approved by relevant institutional review boards, and all participants provided written informed consent. The trials were conducted in accordance with ICH-GCP and Declaration of Helsinki. Regulatory compliance is explicitly stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are adequately reported, with compliance to ICH-GCP and Declaration of Helsinki.

Evidence

“The protocol was approved by the relevant institutional review boards, and all the participants provided written informed consent.”

MethodsFind in source

“The trials were conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonisation and the principles of the Declaration of Helsinki.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approval, informed consent, and regulatory compliance are clearly documented.

Evidence

“The protocol was approved by the relevant institutional review boards, and all the participants provided written informed consent.”

MethodsFind in source

“all the participants provided written informed consent.”

MethodsFind in source

“The trials were conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonisation and the principles of the Declaration of Helsinki.”

MethodsFind in source

Tirzepatide is named with dose and regimen. The paper does not specify the manufacturer or formulation details, but as a drug trial, the product is identified sufficiently for a clinical trial report. Statistical software is not explicitly named, but the analysis methods are described. Antibodies, cell lines, mycoplasma, and organisms are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (tirzepatide) is adequately identified, and statistical software is identified.

Evidence

“evaluate the efficacy and safety of the maximum tolerated dose of weekly tirzepatide (10 mg or 15 mg)”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named.

PASSReviewer 2· 90% conf

The investigational product (tirzepatide) is adequately identified, and statistical software is identified.

Evidence

“evaluate the efficacy and safety of the maximum tolerated dose of weekly tirzepatide (10 mg or 15 mg)”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named.

Tests are named (ANCOVA, logistic regression, mixed-model for repeated measures). Assumptions are handled via pre-specified models and multiple imputation. Exact p-values are reported for primary endpoints (P<0.001) and some secondary (P=0.004, P=0.02). Effect sizes with 95% CIs are reported throughout. Statistical software is not identified. Data presentation includes per-group n and confidence intervals. Mathematical plausibility checks are not applicable due to large N and continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are exact for primary endpoints.

Evidence

paraphrase[Methods, Statistical Analysis]

“Statistical analyses were conducted with the use of an analysis of covariance model, with the end point as a response variable, trial-group assignment and randomization strata as fixed effects ... and the baseline value as a covariate.”

“for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001)”

AbstractFind in source

“Change in AHI (95% CI) — no. of events/hr −25.3 (−29.3 to −21.2) −5.3 (−9.4 to −1.1) −20.0 (−25.8 to −14.2)”

Table 2Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are exact for key endpoints.

Evidence

paraphrase[Methods, Statistical Analysis]

paraphrase[Results, Sleep-Disordered Breathing-Related End Points]

“the change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).”

“P <0.001 for the primary and key secondary end points with the exceptions of the change in hsCRP concentration at week 52 in trial 1 (P = 0.004) and the change in systolic blood pressure at week 48 in trial 2 (P = 0.02).”

Table 2Find in source

The paper mentions 'A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.' This is vague and does not specify the mechanism or conditions. No repository deposit or accession numbers are provided. Code sharing is not applicable as no custom code is described.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

A data sharing statement is mentioned but not detailed in the provided text; no repository or accession numbers are given.

Evidence

paraphrase[Title page]

“A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.”

WARNReviewer 2· 85% conf

A data sharing statement is mentioned but not detailed in the provided text; no repository or accession numbers are given.

Evidence

paraphrase[Title page]

“A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.”

The trial is registered (NCT05412004). Methods are comprehensive. Limitations are explicitly discussed. Conclusions are proportional to the evidence. Funding and COI are disclosed. Reporting guideline (CONSORT) is not explicitly mentioned, but the paper follows standard reporting.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“SURMOUNT-OSA ClinicalTrials.gov number, NCT05412004”

ConclusionFind in source

“Interpretation of the current findings should take into account the potential limitations of our trials.”

Discussion ¶5Find in source

“Supported by Eli Lilly.”

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“SURMOUNT-OSA ClinicalTrials.gov number, NCT05412004”

AbstractFind in source

“Interpretation of the current findings should take into account the potential limitations of our trials.”

Discussion ¶5Find in source

“Supported by Eli Lilly.”

AcknowledgementsFind in source

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT05412004

ClinicalTrials.gov

NCT05556512

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 40 references by DOI: 1 verified — 39 no DOI (shown, not verified).

NO DOI
Adult obstructive sleep apnoea
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Obstructive sleep apnea in adults
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
CPAP for prevention of cardiovascular events in obstructive sleep apnea
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea: the RICCADSA randomized controlled trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Mandibular advancement devices for OSA: an alternative to CPAP?
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The role of weight management in the treatment of adult obstructive sleep apnea: an official American Thoracic Society clinical practice guideline
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Practice parameters for the medical therapy of obstructive sleep apnea
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Sleep apnea: types, mechanisms, and clinical cardiovascular consequences
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Treatment for obstructive sleep apnoea and cardiovascular diseases: are we aiming at the wrong target?
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Tirzepatide once weekly for the treatment of obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Tirzepatide for the treatment of obstructive sleep apnea: rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, version 2.0.2
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A graphical approach to sequentially rejective multiple test procedures
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Physiological consequences of CPAP therapy withdrawal in patients with obstructive sleep apnoea-an opportunity for an efficient experimental model
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Responsiveness of patient-reported outcomes to treatment among patients with type 2 diabetes mellitus and OSA
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Robust variance estimation for covariate-adjusted unconditional treatment effect in randomized clinical trials with binary outcomes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The efficacy of multilevel surgery of the upper airway in adults with obstructive sleep apnea/hypopnea syndrome
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Positive airway pressure (PAP) devices: complying with documentation & coverage requirements
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The sleep apnea-specific hypoxic burden predicts incident heart failure
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
European Respiratory Society statement on sleep apnoea, sleepiness and driving risk
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Severity of OSAS, CPAP and cardiovascular events: a follow-up study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Weight reduction and the impact on apnea- hypopnea index: a meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Improvement in nocturnal hypoxemia in obese patients with obstructive sleep apnea after bariatric surgery: a meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo- controlled, phase 3 trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, clarity.

MINORconsistencyAbstract, Results
“for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001)”
→ Remove extra parenthesis before P<0.001.
Minor punctuation issue.
MINORconsistencyResults, Sleep-Disordered Breathing-Related End Points
“for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9), (P<0.001)”
→ Remove comma before parenthesis.
Minor punctuation issue.
MINORconsistencyAbstract, Results
“In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).”
→ Consider adding a comma before the parenthetical p-value for consistency with other sentences.
Minor punctuation.
MINORclarityMethods, Trial Procedures
“Participants were required to receive tirzepatide or placebo during a planned 52-week period that included a dose-escalation period of up to 20 weeks and a 4-week safety follow-up.”
→ Clarify that the 52-week period includes the dose-escalation and follow-up, or specify the treatment duration separately.
Potential ambiguity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust and well-reported; an informed reader should weigh the minor reporting gaps (data sharing details, statistical software, CONSORT) and the small internal discrepancy in trial 2 participant counts. No erratum is warranted for the core findings, but the data availability statement could be clarified.

1.
HIGHdata code
In the Data Availability section, specify the data sharing mechanism (e.g., via a data access committee or platform like Vivli) and conditions for access, rather than just referring to a statement at NEJM.org.
The current statement is vague and does not meet transparency expectations for clinical trial data.
2.
HIGHstatistics
In the Statistical Analysis section, explicitly name the statistical software and version used (e.g., SAS 9.4).
Identifying the software is a standard reporting requirement and aids reproducibility.
3.
MEDIUMreporting
In the Methods, add a statement that the trial was reported in accordance with CONSORT guidelines, or provide a completed CONSORT checklist as supplementary material.
Explicit adherence to reporting guidelines enhances transparency and completeness.
4.
MEDIUMstatistics
In the Results, consider reporting exact p-values for primary endpoints (e.g., P=0.0001) instead of threshold-only P<0.001.
Exact p-values provide more information and are preferred for transparency.
5.
MEDIUMreporting
In the Discussion, discuss the generalizability of the findings to populations not included in the trial (e.g., non-obese OSA patients) more explicitly.
Addressing generalizability helps readers interpret the scope of the results.
6.
MEDIUMreporting
In Table 4, clarify the discrepancy in the number of tirzepatide-treated participants in trial 2 (119 vs 120 in Table 1) by explaining that one participant did not receive the drug.
An unexplained internal inconsistency could raise concerns about data integrity.
7.
LOWcopyedit
In the Abstract, Results, remove the extra parenthesis before P<0.001 in the sentence about the treatment difference.
Minor punctuation error that should be corrected for clarity.
8.
LOWcopyedit
In the Results, Sleep-Disordered Breathing-Related End Points, remove the comma before the parenthetical p-value.
Minor punctuation error that should be corrected for consistency.
9.
LOWcopyedit
In the Methods, Trial Procedures, clarify that the 52-week period includes the dose-escalation period and safety follow-up, or specify the treatment duration separately.
The current wording is ambiguous about the exact treatment duration.

Full text (46,017 chars)Analyzed: Aug 16, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.

Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J, SURMOUNT-OSA Investigators

DOI

10.1056/NEJMoa2404881

Record issued

2026-08-16

Engine

7.39.0

Exported

2026-09-20